SEC
KYMR icon

Seven Eight Capital’s Kymera Therapeutics KYMR Stock Holding History

Seven Eight Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,963
Closed -$642K – 815
2024
Q1 		$642K Sell
15,963
-6,453
-29% -$231K 0.07% 411
2023
Q4 		$571K Buy
+22,416
New +$401K 0.07% 394

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Seven Eight Capital's KYMR Position: Q2 2024 in Review

Seven Eight Capital sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 15,963 shares — an estimated $642K sold.

Seven Eight Capital first reported a position in KYMR in Q4 2023 and held it in 2 quarters. The position peaked at $642K in Q1 2024. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • Seven Eight Capital reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Seven Eight Capital sold 15,963 Kymera Therapeutics shares in Q2 2024, an estimated $642K.
  • Seven Eight Capital first reported a position in Kymera Therapeutics in Q4 2023 and held it in 2 quarters.
  • Seven Eight Capital's Kymera Therapeutics position peaked at $642K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.